We serve Chemical Name:3-(4-methoxyphenyl)-1,2-oxazole CAS:61428-20-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(4-methoxyphenyl)-1,2-oxazole
CAS.NO:61428-20-4
Synonyms:3-(4-Methoxyphenyl)-1,2-oxazol;Isoxazole,3-(4-methoxyphenyl);3-(p-anisyl)isoxazole;3-(4-methoxyphenyl)isoxazole
Molecular Formula:C10H9NO2
Molecular Weight:175.18400
HS Code:2934999090
Physical and Chemical Properties:
Melting point:51-53ºC
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:35.26000
Exact Mass:175.06300
LogP:2.35020
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-(4-Methoxyphenyl)-1,2-oxazol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(4-methoxyphenyl)isoxazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(4-methoxyphenyl)isoxazole Use and application,Isoxazole,3-(4-methoxyphenyl) technical grade,usp/ep/jp grade.
Related News: “We’re going to further invest in research and development to continue to build our pipeline of products, in a more sophisticated way,” he says, holding up a pocket-sized wearable device and a tiny insulin pen to his screen’s camera. “We really believe in this business for the next—we hope—70 years.” 2-Butoxy-5-(trifluoromethyl)pyridine-3-boronic acid manufacturers The business, home to popular brands such as arthritis gel Voltaren and vitamins line Centrum, generated over £10 billion in sales during 2020. 1-(4-Methoxyphenyl)ethanol suppliers The business, home to popular brands such as arthritis gel Voltaren and vitamins line Centrum, generated over £10 billion in sales during 2020. Fluoral-P vendor & factory In 2018, the Bengaluru-based Natural Capsules set up an R&D centre in at Attibele, Bengaluru. In 2020, when PLI scheme was announced it applied for the same. ,The company was one of many to step into the void for needed generic medicines as chronic shortages crippled access to key drugs, specifically in the early- to mid-stages of the pandemic. That shortage actually led the FDA to thaw its relationship with compounding pharmacies — which was once particularly icy — to ramp up production.
